Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer

•No standard of care exists for L2 treatment after L1 chemo-immunotherapy in NSCLC.•Platinum rechallenge and taxane + antiangiogenic are valuable regimens in this setting.•Patients resistant to L1 treatment (PFS

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2023-04, Vol.178, p.116-122
Hauptverfasser:	Auclin, Edouard, Benitez-Montanez, Jose, Tagliamento, Marco, Parisi, Francesca, Gorria, Teresa, Garcia-Campelo, Rosario, Dempsey, Naomi, Pinato, David J., Reyes, Roxana, Albarrán-Artahona, Víctor, Dall'Olio, Filippo, Soldato, Davide, Hendriks, Lizza, Nana, Frank Aboubakar, Tonneau, Marion, Lopez-Castro, Rafael, Nadal, Ernest, Kazandjian, Suzanne, Muanza, Thierry, Blanc-Durand, Félix, Fabre, Elizabeth, Castro, Natalia, Arasanz, Hugo, Rochand, Adrien, Besse, Benjamin, Routy, Bertrand, Mezquita, Laura
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Chemo-immunotherapy Female Humans Immunotherapy Lung Neoplasms - pathology Male Middle Aged Non small cell lung cancer Prognosis Progression-Free Survival Retrospective Studies Second line Survival Taxoids - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	•No standard of care exists for L2 treatment after L1 chemo-immunotherapy in NSCLC.•Platinum rechallenge and taxane + antiangiogenic are valuable regimens in this setting.•Patients resistant to L1 treatment (PFS
ISSN:	0169-5002 1872-8332
DOI:	10.1016/j.lungcan.2023.02.002